New antibody ALTB-268 enters human testing for ulcerative colitis
NCT ID NCT07350577
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called ALTB-268, a monoclonal antibody, in 24 healthy volunteers. The main goal is to check safety and how the body processes the drug. If it passes safety checks, it may later be tested in people with ulcerative colitis to see if it can control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALTB-268 (a monoclonal antibody)
What this could lead to
If successful, this could lead to a new treatment option for ulcerative colitis, helping control the disease and reduce symptoms.
What could go wrong
This is a very early Phase 1 trial in only 24 healthy people, not patients. It only tests safety and dosing, not whether it works for UC. Many early-stage drugs fail to show benefit later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Syneos Health Clinical Research Services, LLC
Miami, Florida, 33136, United States